Research funds pay off with mortality decline

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

The cancer death rate continues to decline, according to the latest report, and at an even faster rate than previously. Cancer mortality decreased by 2.1% per year from 2002 to 2004, almost double the 1.1% decline seen each year from 1993 to 2002.

The cancer death rate continues to decline, according to the latest report, and at an even faster rate than previously. Cancer mortality decreased by 2.1% per year from 2002 to 2004, almost double the 1.1% decline seen each year from 1993 to 2002.

The Annual Report to the Nation, produced by NCI, CDC, the American Cancer Society, and the North American Association of Central Cancer Registries, was published in Cancer (110:2119-2152, 2007), following advance online release.

The biggest contributor to the decline was the fall in colorectal cancer deaths in both men and women, the authors said. Such deaths dropped by 4.9% a year in men and 4.5% in women, due in part to advances in treatment, and new diagnoses of colorectal cancer were down 2.8% in men and 2.4% in women, probably due to colorectal screening.

ASCO president Nancy E. Davidson, MD, attributed the findings to the national investment in cancer research. "These exciting new data demonstrate what many of us in the cancer research and practice community have known for some time. The long-term federal investment in cancer research is paying off," she said, adding that "this impressive pace of progress will slow if we don't recommit to funding cancer research."

Recent Videos
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Related Content